Recombinant Mouse Flt3l, Fc tagged
Cat.No. : | Flt3l-8704M |
Product Overview : | Recombinant Mouse Flt3l (P49772-1) (Met1- Arg188), fused with the Fc region of human IgG1 at the C-terminus, was produced in Human Cell. |
- Specification
- Gene Information
- Related Products
- Citation
- Download
Species : | Mouse |
Source : | Human Cells |
Tag : | Fc |
Protein Length : | 1-188 a.a. |
Form : | Lyophilized from a 0.2μm filtered solution of PBS, pH 7.4 |
Molecular Mass : | The recombinant mouse FLT3L /Fc is a disulfide-linked homodimer. The reduced monomer comprises 403 amino acids and has a predicted molecular mass of 45.4 kDa. The apparent molecular mass of the protein is approximately 56 and 35 kDa in SDS-PAGE under reducing conditions due to glycosylation. |
Endotoxin : | < 1.0 eu per μg of the protein as determined by the LAL method. |
Stability : | Samples are stable for up to twelve months from date of receipt at -70oC. |
Storage : | Store it under sterile conditions at -20oC~-70oC. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles. |
Reconstitution : | It is recommended that sterile water be added to the vial to prepare a stock solution. Centrifuge the vial at 4℃ before opening to recover the entire contents. |
Gene Name | Flt3l FMS-like tyrosine kinase 3 ligand [ Mus musculus (house mouse) ] |
Official Symbol | Flt3l |
Gene ID | 14256 |
mRNA Refseq | NM_013520 |
Protein Refseq | NP_038548 |
UniProt ID | P49772 |
◆ Recombinant Proteins | ||
FLT3L-1888H | Active Recombinant Human FLT3L protein | +Inquiry |
FLT3-1229M | Active Recombinant Macaca mulatta FLT3 Ligand | +Inquiry |
Flt3l-285F | Active Recombinant Mouse Flt3l Protein, His-tagged | +Inquiry |
Flt3l-26M | Active Recombinant Mouse Flt3l Protein (Gly27-Arg188), C-His tagged, Animal-free, Carrier-free | +Inquiry |
Flt3l-188M | Recombinant Mouse FMS-like Tyrosine Kinase 3 Ligand | +Inquiry |
◆ Cell & Tissue Lysates | ||
FLT3LG-1387MCL | Recombinant Mouse FLT3LG cell lysate | +Inquiry |
A new cancer immunotherapy via simultaneous DC-mobilization and DC-targeted IDO gene silencing using an immune-stimulatory nanosystem.
Journal: International journal of cancer PubMed ID: 29752722 Data: 2019/1/25
Authors: Yujuan Zhang, Jiamin Fu, Weiping Min
Article Snippet:Three days after tumor cell inoculation, the tumor-bearing mice were treated with PBS (control), man-GNR, PEI-GNR-siIDO, or man-GNR-siIDO (wt(PEI-GNR or man-GNR):wt(siRNA) = 400 μg:80μg) with 5-day intervals, until endpoint (day 22) of experiment.Three days after tumor cell inoculation, the tumor-bearing mice were treated with PBS (control), man-GNR, PEI-GNR-siIDO, or man-GNR-siIDO (wt(PEI-GNR or man-GNR):wt(siRNA) = 400 μg:80μg) with 5-day intervals, until endpoint (day 22) of experiment.. For the combination treatment, the last of group mice were treated with man-GNR-siIDO, as described above, along with i.v. injection of Flt3-L (Creative BioMart, US) (10 μg/day/mouse) for 8 consecutive days.. All the mice were sacrificed on day 22.All the mice were sacrificed on day 22.
Not For Human Consumption!
Inquiry
- Reviews (0)
- Q&As (0)
Ask a Question for All Flt3l Products
Required fields are marked with *
My Review for All Flt3l Products
Required fields are marked with *